HSP and CD279 gene expression as candidate biomarkers in symptomatic LGLL patients
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1142939 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Stemming from preliminary results obtained by single cell-RNAseq we investigated by qPCR HSP and IFIT gene families in 27 LGLL patients (23 T-LGLL and 4 NK-LGLL), including 11 with neutropenia and/or thrombocytopenia and 16 asymptomatic for the disease. HSP90AA1 and HSPA1B, among HSP family and CD279 exhibit a significantly higher expression in CD3+ CD57+ sorted cells of symptomatic LGLL patients compared to asymptomatic patients and healthy controls. Also, monocytes derived from symptomatic LGLL patients express high levels of CCL3, CCL4 and CCL5 mRNA and of IL-1β, IL-6, TNF, and PD-L1 mRNA, thus confirming a pro-inflammatory cytokine profile reminiscent of a non-classical phenotype. HSP90AA1 and HSPA1B, among HSP family and CD279 exhibit a significantly higher expression in CD3+ CD57+ sorted cells of symptomatic LGLL patients compared to asymptomatic patients and healthy controls. Also, monocytes derived from symptomatic LGLL patients express high levels of CCL3, CCL4 and CCL5 mRNA and of IL-1β, IL-6, TNF, and PD-L1 mRNA, thus confirming a pro-inflammatory cytokine profile reminiscent of a non-classical phenotype. HSP90AA1 and HSPA1B, among HSP family and CD279 exhibit a significantly higher expression in CD3+ CD57+ sorted cells of symptomatic LGLL patients compared to asymptomatic patients and healthy controls. Also, monocytes derived from symptomatic LGLL patients express high levels of CCL3, CCL4 and CCL5 mRNA and of IL-1β, IL-6, TNF, and PD-L1 mRNA, thus confirming a pro-inflammatory cytokine profile reminiscent of a non-classical phenotype.
2024-11-09 | GSE273729 | GEO
Project description:Human PBMCs: Patients with HSPN vs. Patients with HSP
| PRJNA627966 | ENA
Project description:Genes that were up-regulated in acute stage in HSPN patients compared with HSP patients, and that showed over 1.5-fold differences by the comparison between the two groups in the mean expression levels were selected.
2020-11-30 | GSE149333 | GEO
Project description:Background: Cerebral cavernous angiomas with a symptomatic hemorrhage (CASH) have a high-risk of recurrent hemorrhage and serious morbidity. Methods: Eighteen plasma molecules with postulated mechanistic roles in cavernous angioma (CA) pathobiology were investigated in 114 patients and 12 healthy subjects. The diagnostic biomarker of a CASH in the prior year was derived as minimizing the Akaike Information Criterion (AIC) and validated using machine-learning, and then compared to the prognostic CASH biomarker predicting bleeding in the subsequent year. Both biomarkers were longitudinally followed in a subset of cases. The biomarkers were queried in the transcriptome of human lesional micro-dissected neurovascular units (NVUs) and in relation to plasma miRNAs from CASH and non-CASH patients. Results: The diagnostic CASH biomarker included a weighted combination of four molecules (sCD14, VEGF, CRP, and IL-10) distinguishing CASH patients with 76% sensitivity and 80% specificity (p=0.0003). The prognostic CASH biomarker included two of these molecules (sCD14 and VEGF) and two others (IL-1β and sROBO-4) was confirmed to predict a bleed in the subsequent year, with 83% sensitivity and 93% specificity (p=0.001). Genes associated with the diagnostic and prognostic CASH biomarkers were differentially expressed in CASH lesional NVUs. Thirteen miRNAs were also differentially expressed in the plasma of CASH patients compared to non-CASH. Conclusion: There are shared and unique biomarkers of recent symptomatic hemorrhage and of future bleeding in CA, and are mechanistically linked to the lesional transcriptome and miRNA regulation. The biomarkers may be applied for risk stratification in clinical trials and developed as a tool in clinical practice.
2019-05-13 | GSE130174 | GEO
Project description:Background: Cerebral cavernous angiomas with a symptomatic hemorrhage (CASH) have a high-risk of recurrent hemorrhage and serious morbidity. Methods: Eighteen plasma molecules with postulated mechanistic roles in cavernous angioma (CA) pathobiology were investigated in 114 patients and 12 healthy subjects. The diagnostic biomarker of a CASH in the prior year was derived as minimizing the Akaike Information Criterion (AIC) and validated using machine-learning, and then compared to the prognostic CASH biomarker predicting bleeding in the subsequent year. Both biomarkers were longitudinally followed in a subset of cases. The biomarkers were queried in the transcriptome of human lesional micro-dissected neurovascular units (NVUs) and in relation to plasma miRNAs from CASH and non-CASH patients. Results: The diagnostic CASH biomarker included a weighted combination of four molecules (sCD14, VEGF, CRP, and IL-10) distinguishing CASH patients with 76% sensitivity and 80% specificity (p=0.0003). The prognostic CASH biomarker included two of these molecules (sCD14 and VEGF) and two others (IL-1β and sROBO-4) was confirmed to predict a bleed in the subsequent year, with 83% sensitivity and 93% specificity (p=0.001). Genes associated with the diagnostic and prognostic CASH biomarkers were differentially expressed in CASH lesional NVUs. Thirteen miRNAs were also differentially expressed in the plasma of CASH patients compared to non-CASH. Conclusion: There are shared and unique biomarkers of recent symptomatic hemorrhage and of future bleeding in CA, and are mechanistically linked to the lesional transcriptome and miRNA regulation. The biomarkers may be applied for risk stratification in clinical trials and developed as a tool in clinical practice.
2019-05-13 | GSE130175 | GEO
Project description:Biomarkers of Cavernous Angioma with Symptomatic Hemorrhage (CASH)
| PRJNA534216 | ENA
Project description:Biomarkers of Cavernous Angioma with Symptomatic Hemorrhage (CASH) [RNA-seq]
| PRJNA534219 | ENA
Project description:We used microarrays to perform systematic profiling of human microRNAs in plasma from nasopharyngeal carcinoma (NPC) patients to find potential biomarkers. By comparing the plasma microRNA profiles of the NPC patients and healthy donors, potential biomarkers for NPC were investigated. A total of 39 microRNAs were aberrantly expressed based on 50 Agilent microarrays containing 887 human microRNAs 50 microarrays containing 887 human microRNAs were used to screen for potential biomarkers with significant differential expression levels between 31 NPC patients and 19 healthy donors.
2013-08-01 | E-GEOD-43329 | biostudies-arrayexpress
Project description:Biomarkers of Cavernous Angioma with Symptomatic Hemorrhage (CASH) [small RNA-seq]
| PRJNA534220 | ENA
Project description:Analysis of neutrophils purified from peripheral blood of patients with symptomatic and pre-symptomatic type 1 diabetes (T1D), at risk of T1D, and healthy controls.
2018-11-30 | GSE110914 | GEO